Certara (NASDAQ:CERT) Updates FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.350-0.410 for the period, compared to the consensus earnings per share estimate of 0.420. The company issued revenue guidance of $395.0 million-$405.0 million, compared to the consensus revenue estimate of $426.1 million.

Certara Trading Down 0.8%

Certara stock opened at $5.09 on Wednesday. The company’s fifty day simple moving average is $6.17 and its 200-day simple moving average is $7.96. The company has a quick ratio of 2.05, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. Certara has a 12 month low of $4.97 and a 12 month high of $13.88. The stock has a market cap of $780.40 million, a P/E ratio of -50.90 and a beta of 1.53.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company had revenue of $106.92 million for the quarter, compared to analysts’ expectations of $106.13 million. During the same quarter in the prior year, the firm earned $0.14 earnings per share. The company’s revenue was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, sell-side analysts forecast that Certara will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Morgan Stanley decreased their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday. Stephens decreased their price objective on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday. Barclays cut their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research report on Tuesday. BMO Capital Markets cut their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Certara in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara has a consensus rating of “Hold” and a consensus price target of $8.85.

Key Certara News

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara said its AI investments are expected to support long-term growth, which could improve the company’s competitive positioning over time. Certara says AI investments will drive long-term growth – but traders are focused on one warning
• Neutral Sentiment: Certara guided 2026 revenue to $395 million-$405 million after divesting its medical writing business, giving investors a clearer picture of the company’s post-divestiture growth profile. Certara expects $395M-$405M 2026 revenue following medical writing divestiture
• Negative Sentiment: Multiple analysts lowered price targets after the earnings update, including Morgan Stanley to $10, Stephens to $9, Craig Hallum to $8, Barclays to $6.50, and Baird to $6, reinforcing a more cautious near-term outlook for CERT. Certara (NASDAQ:CERT) Price Target Lowered to $10.00 at Morgan Stanley
• Negative Sentiment: The company missed Q1 earnings estimates, and market coverage noted that the weak full-year guidance overshadowed the revenue beat, contributing to the stock’s decline. Certara Shares Slide on Outlook Cut, 1Q Loss
• Negative Sentiment: A shareholder investigation notice from Johnson Fistel may add legal overhang and investor uncertainty around Certara’s management disclosures. Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors LP raised its position in Certara by 28.6% in the third quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock worth $212,608,000 after purchasing an additional 3,865,455 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Certara by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 8,387,484 shares of the company’s stock worth $73,894,000 after purchasing an additional 35,203 shares in the last quarter. Deerfield Management Company L.P. raised its position in Certara by 71.7% in the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after purchasing an additional 2,813,438 shares in the last quarter. Ameriprise Financial Inc. raised its position in Certara by 27.1% in the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock worth $63,889,000 after purchasing an additional 1,165,064 shares in the last quarter. Finally, State Street Corp grew its stake in Certara by 2.2% during the fourth quarter. State Street Corp now owns 3,918,784 shares of the company’s stock worth $34,524,000 after buying an additional 83,698 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.